(+)-Vincristine
High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
Explore 51 assets in High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
University of California, Davis
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05600686CT.gov Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05097443CT.gov Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT05164770CT.gov Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT01371630CT.gov Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | University of California, Davis | P3 | B · 63 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Rituximab | National Cancer Institute (NCI) | P3 | BB |
| Etoposide | University of Washington | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Prednisone | National Cancer Institute (NCI) | P3 | BB |
| Zanubrutinib | SWOG Cancer Research Network | P3 | B |
| Venetoclax | National Cancer Institute (NCI) | P2/3 | B |
+42 more in the High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (+)-Vincristine in High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-high-grade-b-cell-lymphoma-with-myc-and-or-bcl2-andor-bcl6-rearrangement
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →